Company / R&D Expense
Supernus Pharmaceuticals, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$106.2M
FY2025
5-year range
$74.6M / $108.8M
FY2021-FY2025
Trend
-2.4%
vs FY2024
Sector context
#140 of 210
Health Care
What the data says
At $106M, Supernus Pharmaceuticals, Inc.'s r&d expense ranks #140 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $20M in FY2016 to $109M in FY2024.
Based on SEC 10-K filings.
$106M in FY2025 with a 5-year CAGR of +6.9%.
Improved from $92M to $106M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +12.5%
- 5-Year CAGR
- +6.9%
- 10-Year CAGR
- -
Sector benchmark
#140 of 210 in Health CareTop 67% of 210This company $106.2M Sector average $644.1M
▼
-83.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 2.4% year-over-year.
- Ranks #140 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $106.2M | -2.4% |
| FY2024 | $108.8M | +18.8% |
| FY2023 | $91.6M | +22.9% |
| FY2022 | $74.6M | -17.6% |
| FY2021 | $90.5M | +19.1% |
| FY2020 | $76.0M | +9.9% |
| FY2019 | $69.1M | +61.5% |
| FY2018 | $42.8M | +46.9% |
| FY2017 | $29.1M | +48.8% |
| FY2016 | $19.6M | -32.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026